In 2025 Tivic Health completed its strategic transformation into an immunotherapy company by acquiring exclusive global rights to its Entolimod platform, including next-generation molecule Entolasta. The company advanced regulatory readiness and initiated funding discussions with U.S. government agencies such as BARDA, Defense Threat Reduction Agency and NIAID for acute radiation syndrome countermeasure development while laying groundwork for oncology supportive care applications.

Tivic established Velocity Bioworks as a wholly owned contract development and manufacturing organization by acquiring biomanufacturing assets and hiring 45 employees, significantly reducing internal production timelines and costs. Velocity Bioworks will also serve third-party clients as a CDMO, creating an immediate new revenue stream and supporting long-term margin growth objectives.

Operating expenses rose to $7.9 million in 2025 from $4.5 million in 2024, driven by biologics licensing, increased headcount and the formation of CDMO operations. Net loss before discontinued operations widened to $8.8–9.1 million versus $5.7 million in 2024, while year-end cash and equivalents soared to $12.6 million, bolstering working capital to $12.4 million.

The company plans to advance its neutropenia program into physician-sponsored clinical trials later this year and explore funding or procurement arrangements for Entolimod as a national preparedness asset. Discontinuation of non-core consumer product operations and relocation of headquarters to San Antonio further streamline the focus on immunotherapy and manufacturing growth.